Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.

Mycoses

Medizinische Klinik III, Charité Campus Benjamin Franklin, Freie Universität, Berlin, Germany.

Published: May 2007

Recently, improved response and survival rates in patients treated with voriconazole and neurosurgery for central nervous system (CNS) aspergillosis have been reported. We assessed retrospectively the outcome in 17 patients with definite or probable CNS aspergillosis treated with amphotericin B alone (n = 15) or in combination with 5-fluorocytosine (n = 3) or itraconazole (n = 2). Four patients underwent neurosurgery. The mortality rate was 100% with a median survival of only 10 days (range: 3-60) after onset of first symptoms or first radiological evidence of CNS aspergillosis. In conclusion, treatment with amphotericin B and itraconazole has negligible efficacy in CNS aspergillosis.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1439-0507.2007.01345.xDOI Listing

Publication Analysis

Top Keywords

cns aspergillosis
20
cns
5
aspergillosis
5
poor efficacy
4
efficacy amphotericin
4
amphotericin b-based
4
b-based therapy
4
therapy cns
4
aspergillosis improved
4
improved response
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!